Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.82 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.82 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 3/20 | 0.79 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | FABP3 | P05413 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | GMNN | O75496 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | BLM | P54132 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19092850 | 1.00 | SMN1; SMN2 (0.82) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL22479276 | 1.00 | SMN1; SMN2 (0.82) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL6811206 | 0.94 | SMN1; SMN2 (0.73) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL122604 | 0.94 | SMN1; SMN2 (0.73) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL19821335 | 0.94 | SMN1; SMN2 (0.73) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL2297058 | 0.94 | SMN1; SMN2 (0.82) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL20143295 | 0.92 | RECQL (0.71) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL1965814 | 0.92 | RECQL (0.71) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL564851 | 0.92 | ALDH1A1 (0.73) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL417340 | 0.92 | ALDH1A1 (0.73) | SMN1; SMN2NR5A2NR5A1MAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014079-A1 | CAROTENOID COMPOSITIONS AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-01-15 | — | — | US | claimed |
| US-20250268839-A1 | PROMOTING TRAINED IMMUNITY WITH THERAPEUTIC NANOBIOLOGIC COMPOSITIONS | STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (NL) | 2025-08-28 | — | — | US | claimed |
| US-20220409565-A1 | CAROTENOID COMPOSITIONS AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2022-12-29 | — | — | US | claimed |
| CN-112236134-A | Carotenoid compositions and uses thereof | L.E.A.F.控股集团公司 | 2021-01-15 | — | — | CN | claimed |
| US-8252775-B2 | Method of treating multiple sclerosis with phosphocholine containing lipids | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-08-28 | — | — | US | claimed |
| US-20260130855-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622874-B2 | Trans-crocetin compositions and treatment regimens | L.E.A.F. HOLDINGS GROUP LLC (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260053806-A1 | GAMMA POLYGLUTAMATED METHOTREXATE AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260048054-A1 | ALPHA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260014079-A1 | CAROTENOID COMPOSITIONS AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-3706801-B1 | PLATINUM COMPLEXES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-4667017-A2 | CAROTENOID COMPOSITIONS AND USES THEREOF | L.E.A.F Holdings Group LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| CN-111936146-A | Alpha polyglutamated tetrahydrofolic acid and application thereof | L.E.A.F.控股集团公司 | 2020-11-13 | — | — | CN | disclosed |
| CN-111936145-A | Gamma polyglutamated methotrexate and uses thereof | L.E.A.F.控股集团公司 | 2020-11-13 | — | — | CN | disclosed |
| CN-111867593-A | Alpha polyglutamated antifolate agent and its use | L.E.A.F.控股集团公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2019160732-A1 | GAMMA POLYGLUTAMATED AMINOPTERIN AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC (US) | 2019-08-22 | — | — | WO | disclosed |
| WO-2019157148-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC (US) | 2019-08-15 | — | — | WO | disclosed |
| WO-2019157138-A1 | ALPHA POLYGLUTAMATED PEMETREXED AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC (US) | 2019-08-15 | — | — | WO | disclosed |
| WO-2019157120-A1 | ALPHA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC (US) | 2019-08-15 | — | — | WO | disclosed |
| US-20190231690-A1 | PLATINUM COMPLEXES AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2019-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622874-B2 | Trans-crocetin compositions and treatment regimens | CPT2, SOD1, TFRC | SMN1; SMN2 418/4885NR5A2 3415/4885NR5A1 3289/4885 |
| US-20220409565-A1 | CAROTENOID COMPOSITIONS AND USES THEREOF | STARD7, LRAT, HCCS | SMN1; SMN2 1948/4885NR5A2 3044/4885NR5A1 1044/4885 |
| US-20190231690-A1 | PLATINUM COMPLEXES AND USES THEREOF | ERCC5, TOP1, TOP2A | SMN1; SMN2 783/4885NR5A2 4584/4885NR5A1 4004/4885 |
| US-20260048054-A1 | ALPHA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOF | FOLR2, FOLR1, FPGS | SMN1; SMN2 3305/4885NR5A2 3569/4885NR5A1 3267/4885 |
| US-20260053806-A1 | GAMMA POLYGLUTAMATED METHOTREXATE AND USES THEREOF | FPGS, PDF, STOML2 | SMN1; SMN2 3940/4885NR5A2 4487/4885NR5A1 4647/4885 |
| US-20260130855-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | FOLR2, FPGS, FOLR1 | SMN1; SMN2 4549/4885NR5A2 3324/4885NR5A1 3599/4885 |
| US-20260014079-A1 | CAROTENOID COMPOSITIONS AND USES THEREOF | STARD7, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CPT2 | SMN1; SMN2 736/4885NR5A2 3199/4885NR5A1 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.